Rivaroxaban For Suspension — FDA Drug Shortage

To Be Discontinued — Janssen Pharmaceuticals

The FDA lists a drug shortage record for Rivaroxaban For Suspension from Janssen Pharmaceuticals with status To Be Discontinued. The shortage was first posted on Sep 18, 2026.

Shortage details

Status
To Be Discontinued
Company
Janssen Pharmaceuticals
Package NDC
50458-575-01
Presentation
Xarelto, For Suspension, 155 mg (NDC 50458-575-01)
Initial Posting
Sep 18, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.